Due to the fact that insufficient tumour tissue for molecular testing is common in pancreatic cancer in addition to the high prevalence of KRAS mutations in pancreatic tumour tissues (> 90%), KRAS mutational status on circulating tumour DNA has also been assessed as a diagnostic and prognostic tool with varying levels of success (Brychta et al. 2016; Buscail et al. 2020; Zorde Khvalevsky et al. 2013). Here, KRAS is linked to familial pancreatic carcinoma.